Effects of mosapride, a 5-hydroxytryptamine 4 receptor agonist, on electrical activity of the small intestine and cecum in horses.
OBJECTIVE
To examine the effects of various doses of mosapride, a 5-hydroxytryptamine 4 receptor agonist, on motility of the small intestine and cecum in horses by use of electrical activity and to determine the dose that provides the optimal response.


METHODS
6 healthy adult Thoroughbreds.


METHODS
Electrical activity of the small intestine and cecum was recorded before and after mosapride administration by use of an electrogastrograph. Mosapride (0.5, 1, 1.5, and 2 mg/kg) was dissolved in 200 mL of water and administered orally to horses through a nasogastric tube. Three hours after drug administration, mean amplitude of electrical activity calculated for a period of 30 minutes was expressed as the percentage of the mean amplitude of electrical activity for a period of 30 minutes before drug administration.


RESULTS
Mosapride administered orally increased the percentage of the mean amplitude of electrical activity in the small intestine and cecum in a dose-dependent manner. Mean +/- SD values differed significantly for 1, 1.5, and 2 mg/kg (127.0 +/- 12.5%, 137.7 +/- 22.2%, and 151.1 +/- 24.0%, respectively) in the small intestine and for 1.5 and 2 mg/kg (130.1 +/- 34.5% and 151.6 +/- 45.2%, respectively) in the cecum.


CONCLUSIONS
Analysis of results of this study clearly documents that mosapride promotes motility in the small intestine and cecum of horses and that the optimal orally administered dosage is 1.5 to 2 mg/kg. Therefore, mosapride may be useful for treatment of horses with gastrointestinal tract dysfunction.
Sasaki
Naoki
N
Department of Veterinary Surgery, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Hokkaido, 080-8555, Japan.
Okamura
Kouichi
K
Yamada
Haruo
H
D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D002432:Cecum / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D005769:Gastrointestinal Motility / Q000187:drug effects; D006736:Horses / Q000502:physiology*; D007421:Intestine, Small / Q000187:drug effects* / Q000502:physiology; D009025:Morpholines / Q000494:pharmacology*; D058828:Serotonin 5-HT4 Receptor Agonists
D001549:Benzamides; D009025:Morpholines; D058828:Serotonin 5-HT4 Receptor Agonists; C062720:mosapride